Abstract
The recent emergence of a previously unknown coronavirus (SARS-CoV-2), first confirmed in the city of Wuhan in China in December 2019, has caused serious public health and economic issues due to its rapid dissemination worldwide. Although 61,888 confirmed cases had been reported in Brazil by 28 April 2020, little was known about the SARS-CoV-2 epidemic in the country. To better understand the recent epidemic in the second most populous state in southeast Brazil (Minas Gerais, MG), we looked at existing epidemiological data from 3 states and sequenced 40 complete genomes from MG cases using Nanopore. We found evidence of multiple independent introductions from outside MG, both from genome analyses and the overly dispersed distribution of reported cases and deaths. Epidemiological estimates of the reproductive number using different data sources and theoretical assumptions all suggest a reduction in transmission potential since the first reported case, but potential for sustained transmission in the near future. The estimated date of introduction in Brazil was consistent with epidemiological data from the first case of a returning-traveler from Lombardy, Italy. These findings highlight the unique reality of MG’s epidemic and reinforce the need for real-time and continued genomic surveillance strategies as a way of understanding and therefore preparing against the epidemic spread of emerging viral pathogens.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Pan American World Health Organization (PAHO) (VPGDI-003-FIO-19-2-2-30). MG is supported by Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ). V.F. and T.d.O. are supported by the South African Medical Research Council (MRC-RFA-UFSP-01-2013/UKZN HIVEPI) and the NIH H3AbioNet network, which is an initiative of the Human Health and Heredity in Africa Consortium (H3Africa). E.C.H. is supported by an Australian Research Council Australian Laureate Fellowship (FL170100022). J.L. is supported by a lectureship from the Department of Zoology, University of Oxford. J.X. and F.I is supported by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES) - Finance Code 001. F.I. is also supported by Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG). A.S. has a scholarship from ZIKA-Announcement MCTIC/FNDCT-CNPq/MEC - CAPES/MS-Decit /No. 14/2016 - Prevention and Fight against Zika Virus. M.T.L. is supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPQ). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
SARS-CoV-2 genome sequences generated in this study have been deposited in the GISAID platform (https://www.gisaid.org/), accession numbers IDs EPI_ISL_429664 to EPI_ISL_429703.
